BIO-TECHNE Corp (TECH)
Biological Products, (No Diagnostic Substances) · Biological Products, (No Diagnostic Substances) · NASDAQ
$72.48
+0.36%
Investingg Score
47.6 / 100
Sell
Business overview
- Gross margin is reported at 64.8%.
- Operating margin stands at 8.4%.
These figures indicate that while the company retains strong pricing power in its gross profit generation, its operating profitability is compressed by overhead or operating expenses.
Financial health
- Free cash flow margin is recorded at 21%.
This robust free cash flow margin demonstrates solid cash conversion capabilities relative to the company's revenue.
- Gross Margin
- 64.8%
- Operating Margin
- 8.4%
- Current Ratio
- 3.5x
- Debt / Equity
- Data unavailable
- Free Cash Flow (TTM)
- $0.3B
- Interest Coverage
- 12x
Valuation
- P/E ratio is 74.97 with a forward P/E of 35.21.
- Price-to-sales ratio is 9.28 and free cash flow yield is 2.3%.
These elevated multiples suggest that the stock is priced at a premium relative to current earnings, introducing valuation risk.
- P/E (TTM)
- 75.0x
- Forward P/E
- 35.2x
- Price / Sales
- 9.3x
- EV / EBITDA
- Data unavailable
- FCF Yield
- 2.3%
Key risks
- Severe year-over-year EPS contraction of 56.2% indicates fundamental earnings instability.
- High trailing P/E ratio of 74.97 leaves little margin for execution errors.
- Modest revenue growth of 5.2% limits rapid top-line recovery.
Market cap $11.2B · data as of 2026-08-20
Related stocks
Get the full interactive report
Technicals, earnings history, news, bull/base/bear scenarios, Ask the Stock, and more — free to start.
Analyze TECH with Investingg AINot investment advice. Investingg AI summarizes public data and AI-generated analysis for informational purposes only.